Clinical trials / California
Psychedelic and ketamine trials recruiting in California
17 trials registered on ClinicalTrials.gov were recruiting at one or more sites in California on 26 Oct 2026. By substance: Psilocybin 11, Ketamine / esketamine 4, MDMA 3. By condition: depression 3, ptsd 2, cancer and end-of-life distress 1, eating disorders 1, ocd 2.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Phase 3Ketamine / esketamineNCT07716098
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
- Conditions:
- Depressive Disorder, Treatment-Resistant
- Sponsor:
- Janssen Research & Development, LLC
- Who:
- ages 18 Years and over, 348 participants planned
- Also in:
- Japan, Taiwan
- Anderson Clinical Research, Redlands, California
- Artemis Institute for Clinical Research, San Diego, California
Phase 1PsilocybinNCT07516405
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults (Psil-Pk)
- Conditions:
- Healthy Volunteer; Older Adults (65-85 Years)
- Sponsor:
- University of Colorado, Denver
- Who:
- ages 65 Years to 85 Years, 40 participants planned, accepts healthy volunteers
- University of California San Francisco (UCSF) Department of Neurology, San Francisco, California
Phase 2Psilocybin, Ketamine / esketamineNCT05403086
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC)
- Conditions:
- Demoralization
- Sponsor:
- Charles S. Grob, M.D.
- Who:
- ages 18 Years and over, 100 participants planned
- Marin Cancer Care, Greenbrae, California
- University of California, Los Angeles, Los Angeles, California
- University of San Francisco, San Francisco, California
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California
Phase 2MDMANCT05790239
MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder
- Conditions:
- Post Traumatic Stress Disorder
- Sponsor:
- Stephen Robert Marder
- Who:
- ages 18 Years and over, 40 participants planned
- VA Greater Los Angeles Healthcare System, Westwood campus, Los Angeles, California (not yet recruiting)
- West Los Angeles Veteran Affairs, Los Angeles, California
Phase 2PsilocybinNCT06399263
Study of Psilocybin for Anorexia in Young Adults (SPANYA)
- Conditions:
- Anorexia Nervosa
- Sponsor:
- Marissa Raymond-Flesch, MD, MPH
- Who:
- ages 18 Years to 25 Years, 40 participants planned
- University of California, San Francisco, San Francisco, California (not yet recruiting)
- University of California, San Francisco, San Francisco, California
Phase 1PsilocybinNCT05265546
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain
- Conditions:
- Perception Disorders
- Sponsor:
- University of California, Berkeley
- Who:
- ages 21 Years and over, 80 participants planned, accepts healthy volunteers
- University of California, Berkeley, Berkeley, California
Phase 1/2MDMANCT05770375
Tolerability of MDMA in Schizophrenia (TMS)
- Conditions:
- Schizophrenia
- Sponsor:
- Anya Bershad, MD, PhD
- Who:
- ages 18 Years to 60 Years, 20 participants planned
- UCLA, Los Angeles, California
Phase 2MDMANCT05837845
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
- Conditions:
- PTSD
- Sponsor:
- Patricia Suppes
- Who:
- ages 18 Years and over, 30 participants planned
- VA Palo Alto Health Care System / Stanford University, Palo Alto, California
Phase 2Ketamine / esketamineNCT05940324
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) (MKET2)
- Conditions:
- Obsessive-Compulsive Disorder
- Sponsor:
- Stanford University
- Who:
- ages 18 Years to 65 Years, 150 participants planned, accepts healthy volunteers
- Department of Psychiatry & Behavioral Sciences, Stanford, California
Phase 2PsilocybinNCT06233344
Mindfulness-Assisted Psychedelic Therapy (MAPT)
- Conditions:
- Mental Health
- Sponsor:
- University of Southern California
- Who:
- ages 25 Years and over, 40 participants planned, accepts healthy volunteers
- Univeristy of Southern California Brain and Creativity Institute, Los Angeles, California
Phase 1PsilocybinNCT06367738
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
- Conditions:
- Aging
- Sponsor:
- University of California, Berkeley
- Who:
- ages 60 Years to 85 Years, 40 participants planned, accepts healthy volunteers
- University of California, Berkeley, Berkeley, California
Phase 2PsilocybinNCT06455293
Psilocybin Therapy for Depression in Parkinson's Disease (PDP2)
- Conditions:
- Parkinson Disease; Depression
- Sponsor:
- Joshua Woolley, MD, PhD
- Who:
- ages 40 Years to 80 Years, 60 participants planned
- University of California, San Francisco, San Francisco, California
Phase 1/2Ketamine / esketamineNCT06575075
Pilot Study of RR-HNK in OCD ((HNKO))
- Conditions:
- Obsessive-Compulsive Disorder
- Sponsor:
- Carolyn Rodriguez
- Who:
- ages 18 Years to 65 Years, 45 participants planned
- Stanford University School of Medicine, Palo Alto, California
Phase 2PsilocybinNCT06626139
Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers (SnS)
- Conditions:
- Healthy Participants With Lower-than-average Mental Well-being
- Sponsor:
- Robin Carhart-Harris, PhD, MA
- Who:
- ages 21 Years to 70 Years, 120 participants planned, accepts healthy volunteers
- UCSF Mission Bay, San Francisco, California
Phase 1/2PsilocybinNCT06814522
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout (PAT-B)
- Conditions:
- Burnout; Burnout, Healthcare Workers
- Sponsor:
- University of California, San Diego
- Who:
- ages 21 Years to 70 Years, 30 participants planned
- UC San Diego, San Diego, California
Phase 1/2PsilocybinNCT07281352
RCT of Psilocybin-assisted CBT for Depression
- Conditions:
- Major Depressive Diorder
- Sponsor:
- University of California, Los Angeles
- Who:
- ages 21 Years to 60 Years, 50 participants planned
- UCLA Semel Institute, Los Angeles, California
Phase 1PsilocybinNCT07386730
A Study of Psychedelics in Healthy Older Adults With Low Well-being (OAD1)
- Conditions:
- Anhedonia in Healthy Volunteers; Older Adults (50-90 Years)
- Sponsor:
- Jennifer Mitchell
- Who:
- ages 50 Years to 85 Years, 80 participants planned, accepts healthy volunteers
- University of California San Francisco, Sandler Neuroscience Building, San Francisco, California